What are appropriate non‑benzodiazepine alternatives to temazepam for managing insomnia in an elderly woman with failure‑to‑thrive?

Alternative to Temazepam for Elderly Female with Failure to Thrive

Low-dose doxepin (3-6 mg) is the preferred alternative to temazepam for this elderly patient, as it effectively improves sleep maintenance with a safety profile comparable to placebo and lacks the serious risks of benzodiazepines in older adults 1, 2.

Why Avoid Temazepam in This Population

Temazepam and other benzodiazepines pose substantial risks in elderly patients that far outweigh their benefits 1:

• Falls and fractures due to oversedation, dizziness, confusion, and ataxia—risks that increase substantially with benzodiazepine use 2
• Cognitive impairment and memory loss (5-fold increase in confusion and disorientation) 3
• Physical dependence and withdrawal complications requiring gradual tapering 2
• Increased mortality demonstrated in observational studies 3
• Next-morning impairment affecting function and safety 3, 2

The FDA label explicitly warns that elderly patients are at especially high risk and recommends only 7.5 mg as the initial dose if benzodiazepines must be used 2. However, VA/DoD guidelines advise against benzodiazepine use for chronic insomnia due to these harms 1.

Recommended Alternatives (in Order of Preference)

First-Line: Low-Dose Doxepin (3-6 mg)

• Efficacy: Improves Insomnia Severity Index scores, sleep latency, total sleep time, and sleep quality in older adults at week 4 1
• Safety: No statistically significant difference in adverse events compared to placebo 1
• Dosing: Start with 3 mg; may increase to 6 mg if needed
• Advantage: Specifically studied and effective in older adults for sleep maintenance 4, 5

Second-Line: Suvorexant (Dual Orexin Receptor Antagonist)

• Efficacy: Improves sleep maintenance with sustained benefit 1, 4
• Safety: Only mild side effects (primarily somnolence); much better tolerated than benzodiazepines 4, 6
• Dosing: 5-10 mg in elderly patients
• Consideration: Newer agent with less long-term data but favorable risk profile 5

Third-Line: Ramelteon (8 mg)

• Efficacy: Slightly improves sleep-onset latency and total sleep time 4, 5
• Safety: Minimal adverse effect profile, making it valuable for first-line use 7
• Limitation: More effective for sleep-onset rather than sleep-maintenance insomnia 5
• Advantage: No risk of falls, cognitive impairment, or dependence 7

What NOT to Use

Avoid these commonly prescribed alternatives 1:

• Trazodone: Low-quality evidence for efficacy; adverse effects outweigh benefits 1
• Antihistamines (diphenhydramine): Strong recommendation to avoid in older adults per 2019 Beers Criteria due to antimuscarinic effects; tolerance develops after 3-4 days 1, 7
• Antipsychotics (quetiapine): Sparse evidence, serious adverse effects, inappropriate for primary insomnia 1
• Z-drugs (zolpidem, eszopiclone, zaleplon): While better than benzodiazepines, still associated with dementia, fractures, major injuries, and complex sleep behaviors like sleep-driving 1, 3, 7

Clinical Algorithm for This Patient

1. Assess underlying causes: In failure-to-thrive patients, insomnia may reflect unrecognized medical illness, depression, pain, or medication side effects 2. Address these first.

2. Start low-dose doxepin 3 mg at bedtime:

   • Titrate to 6 mg after 1 week if inadequate response
   • Monitor for morning sedation (though rare at these doses)
   • Reassess sleep quality at 2-4 weeks

3. If doxepin ineffective or not tolerated, switch to suvorexant 5 mg:

   • Particularly useful if sleep maintenance is the primary problem
   • Monitor for next-day somnolence

4. If sleep-onset latency is the main issue, consider ramelteon 8 mg taken 30 minutes before bedtime

5. Taper temazepam gradually using a patient-specific plan to avoid withdrawal seizures 2:

   • Reduce by 25% every 1-2 weeks
   • Monitor for rebound insomnia, anxiety, or withdrawal symptoms
   • Provide psychosocial support during withdrawal 8

Important Caveats

• Withdrawal from chronic benzodiazepine use may actually improve sleep and quality of life within 6 months in older adults 8. Many patients experience shorter sleep-onset latency and less daytime fatigue after successful withdrawal.

• Cognitive behavioral therapy for insomnia (CBT-I) should be pursued concurrently as it is the gold standard treatment 1, 9, 7. However, pharmacotherapy is appropriate when symptoms persist or CBT-I is not accessible.

• In failure-to-thrive patients, addressing nutritional status, depression, social isolation, and comorbid medical conditions is essential—insomnia may be a symptom rather than a primary disorder 2.

• All hypnotics carry some risk of next-morning impairment affecting driving and falls 3. Use the lowest effective dose for the shortest duration necessary.